更正:B7-H3 CAR-T 细胞清除肝内胆管癌并诱导持久应答
Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.
肿瘤细胞治疗研究
英文原题:Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report.
Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本病例研究探讨了自体细胞因子诱导的杀伤(CIK)细胞免疫治疗在一名49岁男性不可手术的IIIb期胆管癌患者中的有效性,该患者免疫细胞中钠依赖性维生素C转运体-2(SVCT2)水平较高。尽管化疗后肿瘤最初未见缩小,但患者在接受放疗和质子治疗后,肿瘤标志物显著下降,肿瘤稳定。随后,CIK细胞治疗联合高剂量维生素C,在6年内共进行52次。患者肿瘤体积缩小,诊断后7年10个月未检测到癌症活动,表明长期结果成功且无复发。本研究提示,CIK细胞治疗,尤其是在SVCT2水平升高的患者中,可能为胆管癌及潜在其他癌症提供一种有前景的辅助治疗。需要进一步研究以验证SVCT2作为CIK细胞治疗有效性的生物标志物。
This case study explores the effectiveness of autologous cytokine-induced killer (CIK) cell-based immunotherapy in a 49-year-old male patient with inoperable stage IIIb cholangiocarcinoma, characterized by high levels of the sodium-dependent vitamin C transporter-2 (SVCT2) in immune cells.
Despite an initial lack of tumor reduction following chemotherapy, the patient showed a significant decrease in tumor markers and stabilization of the tumor after undergoing radiation and proton therapy. Subsequently, CIK cell therapy, combined with high-dose vitamin C, was administered 52 times over 6 years. The patient's tumor size reduced, and no cancer activity was detected for 7 years and 10 months post-diagnosis, indicating a successful long-term outcome without recurrence.
This study suggests that CIK cell therapy, particularly in patients with elevated SVCT2 levels, may offer a promising adjuvant treatment for cholangiocarcinoma and potentially other cancers.
Further research is needed to validate SVCT2 as a biomarker for the effectiveness of CIK cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。